Cohort-based pan-cancer analysis and experimental studies reveal ISG15 gene as a novel biomarker for prognosis and immunotherapy efficacy prediction
Cancer Immunology, Immunotherapy · 10.04.2025 · 74 (5)
DOI: 10.1007/s00262-025-04026-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 10.04.2025. Verfasst von Jingjing Wei und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Ubiquitins, Biomarkers, Tumor, Immunotherapy, Cytokines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nanjing Health Science and Technology development special fund project, the National Natural Science Foundation of China, the Natural Science Foundation of Jiangsu Province for Excellent Young Scholars.
Abstract (Originalsprache)
ISG15, an interferon-stimulated ubiquitin-like protein, plays a multifaceted role in tumorigenesis and immune regulation. This study comprehensively evaluates ISG15 as a prognostic biomarker and predictor of immunotherapy response through pan-cancer bioinformatics analysis and experimental validation. By integrating multiomics data from TCGA, GEO, and clinical cohorts, we found that ISG15 is significantly overexpressed in multiple cancers and generally correlates with poor prognosis. Elevated ISG15 expression is associated with increased immune checkpoint gene expression, particularly PD-L1, and immune infiltration, notably M2-like tumor-associated macrophages. Immunohistochemistry and multiplexed immunofluorescence confirmed a strong positive correlation between ISG15, PD-L1, and M2-TAM infiltration in lung and gastric cancer samples. Functional analysis at the single-cell level revealed significant associations between ISG15 and tumor proliferation, angiogenesis, and immune suppression. Immunotherapy cohort analysis demonstrated that tumors with high ISG15 expression responded favorably to PD-L1 inhibitors but exhibited resistance to CTLA-4 blockade, findings further validated in lung cancer patients receiving anti-PD-1 therapy. These results suggest that ISG15 is a promising biomarker for prognosis and immunotherapy response prediction across cancers. Its integration into clinical decision-making may enhance personalized treatment strategies, improve immunotherapy outcomes, and provide new insights into the tumor immune microenvironment, cancer progression, and potential therapeutic targets for future drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
- Department of Gastroenterology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China.
- Department of Ultrasound, Kunshan Hospital of Traditional Chinese Medicine, Kunshan, Jiangsu, China.
- Department of Gastroenterology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
- Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
- Saratoga High School, 20300 Herriman Ave, Saratoga, CA, USA.
Förderung
- Nanjing Health Science and Technology development special fund project
- the National Natural Science Foundation of China
- the Natural Science Foundation of Jiangsu Province for Excellent Young Scholars
- China Postdoctoral Science Foundation
- fundings for Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University
Zitieren
APA
Wei, J., Zhuang, Y., Jiang, C., Chen, L., Yuan, B., Zhao, Y., Li, H., Mao, J. H., Hang, B., Ye, C., Wang, L., & Wang, P. (2025). Cohort-based pan-cancer analysis and experimental studies reveal ISG15 gene as a novel biomarker for prognosis and immunotherapy efficacy prediction. Cancer Immunology, Immunotherapy, 74(5). https://doi.org/10.1007/s00262-025-04026-y
Vancouver
Wei J, Zhuang Y, Jiang C, Chen L, Yuan B, Zhao Y, et al. Cohort-based pan-cancer analysis and experimental studies reveal ISG15 gene as a novel biomarker for prognosis and immunotherapy efficacy prediction. Cancer Immunology, Immunotherapy. 2025;74(5). doi:10.1007/s00262-025-04026-y
BibTeX
@article{Wei2025,
author = {Wei, Jingjing and Zhuang, Yingjia and Jiang, Chengfei and Chen, Lingyan and Yuan, Binbin and Zhao, Yue and Li, Happi and Mao, Jian-Hua and Hang, Bo and Ye, Chunping and Wang, Lei and Wang, Pin},
title = {Cohort-based pan-cancer analysis and experimental studies reveal ISG15 gene as a novel biomarker for prognosis and immunotherapy efficacy prediction},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
volume = {74},
number = {5},
doi = {10.1007/s00262-025-04026-y}
}
EUVIMED